$14.73
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Overview
52-week range
$3.57
$16
87% of range
Avg surprise (last 3)
+2.6%
Avg reaction (last 2)
+1.2%
100% positive
Latest IV / EM
160%
EM ±36.7% · $15 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.39 | $-0.55 | +29.1% | +37.1% | +1.7% | earnings |
| Tue Aug 5, 2025 | Jun/2025 | $-0.62 | $-0.56 | -10.7% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.62 | $-0.56 | -10.7% | — | +0.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.40 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.39 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.69 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.84 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.46 | -$0.62 | +25.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-17M | — | $-15M | $-18M | $-18M | — | $-13M | $-11M |
| Net income | $-14M | — | $-13M | $-16M | $-16M | — | $-10M | $-9M |
| EPS (diluted) | $-0.39 | — | — | — | $-0.62 | — | $-0.40 | $-0.39 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20M | $76M | $43M | $21M | $22M | $22M | $41M | $77M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $253M | $268M | $185M | $177M | $192M | $206M | $215M | $220M |
| Total assets | $261M | $277M | $191M | $183M | $198M | $213M | $216M | $221M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $16M | $10M | $11M | $13M | $15M | $6M | $4M |
| Total equity | $250M | $261M | $180M | $171M | $185M | $198M | $210M | $218M |